Regeneron Pharmaceuticals, Inc. (LON:0R2M)
London · Delayed Price · Currency is GBP · Price in USD 648.75
-3.50 (-0.54%)
At close: Nov 7, 2025
Regeneron Pharmaceuticals Employees
Regeneron Pharmaceuticals had 15,106 employees as of December 31, 2024. The number of employees increased by 1,656 or 12.31% compared to the previous year.
Employees
15,106
Change (1Y)
1,656
Growth (1Y)
12.31%
Revenue / Employee
696.33K GBP
Profits / Employee
223.74K GBP
Market Cap
51.24B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 15,106 | 1,656 | 12.31% |
| Dec 31, 2023 | 13,450 | 1,599 | 13.49% |
| Dec 31, 2022 | 11,851 | 1,483 | 14.30% |
| Dec 31, 2021 | 10,368 | 1,245 | 13.65% |
| Dec 31, 2020 | 9,123 | 1,023 | 12.63% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| Spire Healthcare Group | 15,703 |
| ConvaTec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| Genus | 3,190 |
Regeneron Pharmaceuticals News
- 18 hours ago - Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60% - Investor's Business Daily
- 21 hours ago - Regeneron Reports Promising Phase 2 Results For Novel Factor XI Antibodies In Knee Surgery Patients - Nasdaq
- 1 day ago - UBS Raises Regeneron Pharmaceuticals (REGN) Price Target to $660 | REGN Stock News - GuruFocus
- 1 day ago - REGN: Regeneron and Sanofi Report Positive Dupixent Trial Results - GuruFocus
- 1 day ago - Regeneron and Sanofi's Dupixent succeeds in late-stage study - Seeking Alpha
- 2 days ago - Sanofi And Regeneron's Dupixent Meets Primary Goal In Phase 3 Allergic Fungal Rhinosinusitis Study - Nasdaq
- 2 days ago - Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review - Benzinga
- 2 days ago - Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review - GlobeNewsWire